Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC ...

US FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx, a companion diagnostic indicated to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma Santa Clara, California ...

The next generation of the industry-proven Agilent MSD — the most popular GC/MS of all time. The 5977A MSD includes a new, highly sensitive Extractor Ion Source for higher Signal-to-Noise (SNR) and a ...

Regulatory changes from the EPA have catalyzed significant innovations in gas chromatography, enhancing analytical capabilities for sulfur emissions monitoring.

The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD candidates with blockbuster potential. According to Reuters, MSD – known as Merck & Co in ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...

Agilent Technologies (A) and Danaher (DHR) screen as potential buyers of Qiagen (QGEN) after a report that the European molecular testing firm is weighing its options after takeover interest. "QGEN ...

The 7820A Gas Chromatography system is an affordable, high-quality GC instrument for small to medium-sized labs concerned with routine analyses. This system provides modern capabilities for a wide ...

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life ...

Access detailed historical stock prices, including daily closing prices, for A. Analyze past performance trends, track price movements, and explore historical data to inform your investment decisions.